©2020 CCRA

CCRA is a 501(c)(3) non-profit organization. 

EIN 82-3762441

  • Facebook
  • Instagram end dog cancer


This is ROSCOE. 


Six-year-old ROSCOE was diagnosed with osteosarcoma in May 2017.

Instead of chemotherapy, he received a new experimental immunotherapy treatment.

He is thriving today with no sign of cancer.

This is CODI. 

His leg was amputated in August 2017 after bone cancer was found.  He also received chemotherapy treatment, which is part of standard-of-care.   But by April 2018, the tumor had metastasized to his lungs.


 The tumors in his lungs disappeared after CODI received a new immunotherapy treatment, and he is still with his parents enjoying life in New Jersey.

Both dogs beat osteosarcoma odds with new immunotherapy


CODI received cancer-fighting vaccine treatment. 

ROSCOE received T-cell infusion as part of what's called "adoptive T-cell therapy".   

Immunotherapy activates the immune system to fight cancer.  For some patients, it can induce long-term remission and even reversal of metastasis.


CCRA supports scientific research and clinical studies to develop new treatments that are far superior to today's therapies.   Immunotherapy is one of the areas of our focus.  Unlike chemotherapy that kills cancer cells directly, immunotherapy helps the dog's own immune cells fight cancer.  It's an approach with potentially fewer side-effects and greater efficacy.


The big challenge for researchers is figuring out how to help all dogs respond like CODI and ROSCOE. 

We must understand the complex interaction between the immune system, the tumor cells, and tumor microenvironment, and come up with the best new treatments that will help our dogs fight cancer.